News Release
View printer-friendly version
|
<< Back |
ZUG, Switzerland and CAMBRIDGE, Mass.,
Date: Wednesday, May 9, 2018
Presentation: 10:40-
Location:
Date:
Presentation:
Location:
A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge,
MEDIA CONTACT:
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com
INVESTOR CONTACT:
+1 617-307-7227 chris.erdman@crisprtx.com
+1 339-970-2843 chris.brinzey@westwicke.com
Source: CRISPR Therapeutics AG